Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, +/- Dasabuvir, +/- Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium

Trial Profile

Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, +/- Dasabuvir, +/- Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Jul 2017

At a glance

  • Drugs Ombitasvir/paritaprevir/ritonavir (Primary) ; Dasabuvir; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 06 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 03 May 2017 Planned number of patients changed from 440 to 300.
    • 03 May 2017 Planned End Date changed from 1 Sep 2018 to 30 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top